Journal profile · BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
MedChemComm
ISSN 2040-2503 · eISSN 2040-2511 · Royal Society of Chemistry · ENGLAND · Founded 2010
MedChemComm: hybrid open access; review 3–8 weeks (community reports); 0 articles in 2025.
Scope
Aims, scope and focus
MedChemComm is published by Royal Society of Chemistry. By OpenAlex counts of its recent articles, its largest topics are Synthesis and biological activity, Computational Drug Discovery Methods and Synthesis and Characterization of Heterocyclic Compounds, together about 48.3% of its articles. Its main subfields are Organic Chemistry. (generated from OpenAlex topic counts and CAS ranking data)
Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
Source: LetPub
Research area (LetPub): BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
Main research topics OpenAlex counts of recent articles; shares are approximate
- Synthesis and biological activityChemistry25.3%
- Computational Drug Discovery MethodsComputer Science12.1%
- Synthesis and Characterization of Heterocyclic CompoundsChemistry11%
- Chemical Synthesis and AnalysisBiochemistry, Genetics and Molecular Biology5.7%
- Microbial Natural Products and BiosynthesisMedicine3.5%
- Click Chemistry and ApplicationsChemistry3%
- Metal complexes synthesis and propertiesMedicine3%
- Receptor Mechanisms and SignalingBiochemistry, Genetics and Molecular Biology2.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Drug Discovery | Q2 | 48/143 | 66th |
| Molecular Medicine | Q2 | 83/165 | 50th |
| Pharmacology | Q2 | 103/301 | 65th |
| Organic Chemistry | Q2 | 57/183 | 69th |
| Biochemistry | Q2 | 172/407 | 57th |
| Pharmaceutical Science | Q2 | 43/169 | 74th |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
Indexed in: no record yet.
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 4.7LetPub ·
- SJR 2026-06
- 0.67LetPub ·
- SNIP 2026-06
- 0.78LetPub ·
- h-index
- 44LetPub ·
- h-index
- 89OpenAlex ·
- i10-index
- 1,457OpenAlex ·
- 2-year mean citedness
- 2OpenAlex ·
- Share of gold OA articles
- 10.61%LetPub ·
Articles by year OpenAlex count · 2,520 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 1 | 0 | 3,249 |
| 2025 | 0 | 0 | 4,755 |
| 2024 | 0 | 0 | 5,385 |
| 2023 | 0 | 0 | 5,366 |
| 2022 | 0 | 0 | 5,707 |
| 2021 | 1 | 0 | 6,149 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- 3–8 weeksLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Royal Society of Chemistry
- Country or region
- ENGLAND
- Founded
- 2010
- ISSN
- 2040-2503
- Electronic ISSN
- 2040-2511
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about MedChemComm
How long does peer review take at MedChemComm?
Authors report an average review time of 3–8 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Is MedChemComm open access, and what is the APC?
MedChemComm is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .